Overview

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Status:
Completed

Trial end date:
2020-07-23

Target enrollment:

Participant gender:

Summary

The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.

Phase:

Phase 2

Details

Lead Sponsor:

Regeneron Pharmaceuticals